Tammie C. Yeh - Concepedia

Author

Tammie C. Yeh

AstraZeneca (United States)

Also Known As

T. C. Yeh, T. Yeh, T.C. Yeh, Tammie C Yeh, Tammie C. Yeh, Tammie Yeh

Publications

1.5K

Citations

H-Index

Concepts

All Affiliations

AstraZeneca (United States)The University of Texas MD Anderson Cancer Center Moffitt Cancer Center University of Washington Seoul National University Hospital

About

Tammie C. Yeh is an author at AstraZeneca (United States) specializing in medicine, pharmacotherapy, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	415
2	Health Sciences	2	2	31
3	Natural Sciences	1	1	33
4	Biochemistry	1	1	18
5	Biology	1	1	33

Tammie C. Yeh

Publications

1.3K

Citations

H-Index

Page 1

	Year	Citations
Biological Characterization of ARRY-142886 (AZD6244), a Potent, Highly Selective Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor Tammie C. Yeh, Vivienne Marsh, Bryan A. Bernat, Clinical Cancer Research	2007	575
AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies Garrett W. Rhyasen, Maureen M. Hattersley, Yi Yao, Molecular Cancer Therapeutics Azd5153 ExposurePathologyPharmacotherapyTumor BiologyMyeloid Neoplasia	2016	147
57O Efficacy, safety and tolerability of MEDI4736 (durvalumab [D]), a human IgG1 anti-programmed cell death-ligand-1 (PD-L1) antibody, combined with gefitinib (G): A phase I expansion in TKI-naïve patients (pts) with EGFR mutant NSCLC Don L. Gibbons, Laura Q.M. Chow, Dongwook Kim, Journal of Thoracic Oncology ImmunologyImmune Checkpoint InhibitorEgfr Mutant NsclcTki-naïve PatientsImmunotherapy	2016	109
Characterization and Cloning of a 58/53-kDa Substrate of the Insulin Receptor Tyrosine Kinase Tammie C. Yeh, Wataru Ogawa, Anne Danielsen, Journal of Biological Chemistry	1996	98
Ponatinib vs Imatinib in Frontline Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia Elias Jabbour, Hagop M. Kantarjian, Ibrahim Aldoss, JAMA	2024	90
A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced/metastatic non-small-cell lung cancer Ben Creelan, Tammie C. Yeh, Sang-We Kim, British Journal of Cancer	2020	71
Potent and Selective Mitogen-Activated Protein Kinase Kinase (MEK) 1,2 Inhibitors. 1. 4-(4-Bromo-2-fluorophenylamino)-1- methylpyridin-2(1<i>H</i>)-ones Eli M. Wallace, Joseph P. Lyssikatos, James F. Blake, Journal of Medicinal Chemistry Mek 1,2Selective InhibitorsPharmacotherapyCancer BiologyPharmaceutical Chemistry	2005	40
Abstract 2515: Preclinical Development of ARRY-162, A Potent and Selective MEK 1/2 Inhibitor Patrice A. Lee, Eli Wallace, Allison Marlow, Cancer Research ImmunologyPharmacotherapySelective Mek 1/2Cancer BiologyTumor Biology	2010	37
Evolution of Rodent Lysozymes: Isolation and Sequence of the Rat Lysozyme Genes Tammie C. Yeh, Allan C. Wilson, David M. Irwin Molecular Phylogenetics and Evolution BiologyRodent LysozymesPhylogeneticsNatural SciencesGenetics	1993	33
Identification of CCR2 and CD180 as Robust Pharmacodynamic Tumor and Blood Biomarkers for Clinical Use with BRD4/BET Inhibitors Tammie C. Yeh, Greg O’Connor, Philip Petteruti, Clinical Cancer Research	2017	24

Page 1